Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$3.04 - $5.14 $51,348 - $86,819
-16,891 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$23.02 - $60.5 $388,830 - $1.02 Million
16,891
16,891 $1.01 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.